Understanding the types of immune responses associated with the control of viral infection is pivotal for the development of effective antiviral vaccine strategies. Several lines of evidence indicate that priming of virus-specific CD4 ϩ T cells might result in protective immunity against immunosuppressive retrovirus infection in humans (6, 31, 35) . However, the observed relationship between priming of CD4 ϩ T cells and protection against retrovirus infections remains circumstantial. Using a mouse model of immunosuppressive Friend retrovirus infection, we previously showed that immunization with a synthetic peptide containing a single CD4 ϩ T-cell epitope resulted in rapid elimination of virus-producing cells from the host and partial protection against the development of fatal leukemia (22) . In these peptide-based experiments animals can be primed with a CD4 ϩ T-cell epitope alone, without other components of the immune system being stimulated before virus inoculation, allowing us to critically analyze the role and mechanisms of CD4 ϩ T-cell help in inducing protective immune effector functions in retrovirus infections.
Friend mouse retrovirus complex (FV) is composed of replication-competent Friend murine leukemia helper virus (FMuLV) and defective spleen focus-forming virus (SFFV), the latter of which induces rapid growth and terminal differentiation of infected erythroid progenitor cells (2, 16) . FV is known to induce fatal erythroleukemia associated with severe immunosuppression when injected into immunocompetent adult mice of susceptible strains (2, 27) . Mice with a BALB/c background are especially susceptible to FV-induced disease because they lack immune and nonimmune mechanisms that render some other strains of mice resistant against FV replication and disease progression (5) . Epitopes recognized by CD4 ϩ helper T cells and CD8 ϩ cytotoxic T lymphocytes (CTL) have been identified in the products of env and gag genes of F-MuLV (1, 15, 20, 32, 36) , and a yet-unidentified immunoprotective CD4 ϩ T-cell epitope has been mapped in the MA (p15) portion of the gag gene product (23) . Among them, two env-derived CD4 ϩ T-cell epitopes, the A b -restricted N-terminal peptide DEPLTSLTPRCNTAWNRLKL (epitope fn) and the C-terminal peptide HPPSYVYSQFEKSYRHKR (epitope i) restricted by the hybrid E b/d molecule, are effective in inducing protective immunity against FV challenge when injected into (B10.A ϫ A.BY)F 1 mice (22) . Production and class switching of virus-neutralizing antibodies after challenge inoculation with live pathogenic Friend retrovirus were accelerated in mice immunized with the synthetic peptides in comparison with unimmunized control mice, and the number of virusproducing cells in the spleen was drastically reduced between 7 and 11 days after the virus inoculation, along with the expansion of CD4 ϩ T cells (22) . To identify effector mechanisms activated after FV infection in mice immunized with the CD4 ϩ T-cell vaccine, spleen cells were separated according to their expression of cell surface markers, and their cytotoxic activities against FV-induced leukemia cells were examined. Both CD8 ϩ and CD4
ϩ T cells constituted a part of effector cells that lysed FV-induced leukemia cells in vitro. However, to our surprise, cells expressing natural killer (NK) cell markers constituted the majority of cytotoxic effector cells in FV-infected mice, and b -restricted N-terminal and E b/d -restricted C-terminal epitopes of the F-MuLV env gene product, respectively, were maintained as described previously (15) . Three other T-cell clones-FP3-10, FP8-7, and FP10-16-were established from CB6F 1 mice immunized with peptide i as described previously (40) Cytotoxicity assays were performed by using 51 Cr-labeled target cells as described elsewhere (20, 30, 39) . Target cells were incubated with 3.7 MBq of 51 Cr/10 6 cells for 1 h and washed three times. When necessary, cells were further incubated for 30 min with a synthetic peptide and washed. Labeled target cells (5 ϫ 10 3 ) were placed in each well of V-bottomed 96-well plates and mixed with effector cells at various effector-to-target (E:T) ratios. Four or twelve hours later, plates were centrifuged and supernatant was collected from each well for measurement of released radioactivity with a gamma counter. Killing activity was calculated by a standard equation: percent specific killing ϭ [( 51 Cr release in a test well Ϫ spontaneous release)/(maximum release Ϫ spontaneous release)] ϫ 100, where maximum release is the radioactivity obtained by adding 1% Triton X-100 into wells of labeled target cells, and spontaneous release is the radioactivity in the supernatant of target cells cultured without effector cells. Data are expressed as means Ϯ standard errors of the means (SEM) of triplicate samples. Inhibition of cytotoxic activity by anti-CD4 or anti-CD8 monoclonal antibody (MAb) was performed by using culture supernatants of relevant hybridoma cells (8, 33) .
Flow cytometry. Flow cytometric analyses of cell surface markers were performed as described elsewhere (12, 19, 34, 40) . Spleen tissue was dissociated in PBBS containing 2% FBS, and single-cell suspension was prepared by passing the dissociated tissue through a nylon mesh. Cells were incubated with a combination of the MAbs listed below, washed three times with PBBS containing 2% FBS and 0.05% NaN 3 , and stained with 20 g of 7-aminoactinomycin D/ml, which was used to exclude dead cells (34) . Antibodies and their final concentrations used in the present study were as follows: fluorescein isothiocyanate (FITC)-conjugated anti-mouse CD4 (rat immunoglobulin G2b [IgG2b]; Seikagaku Corporation, Tokyo, Japan) at 0.5 g/10 6 cells, phycoerythrin (R-PE)-conjugated anti-mouse CD8 (rat IgG2a; Caltag Laboratories, Burlingame, Calif.) at 1 g/10 6 cells, FITC-conjugated anti-mouse CD69 (hamster IgG; PharMingen, San Diego, Calif.) at 1 g/10 6 cells, R-PE-conjugated anti-mouse B220 (rat IgG2a; Coulter Immunology, Hialeah, Fla.) at 0.5 g/10 6 cells, FITC-conjugated anti-NK1.1 (mouse IgG2a; PharMingen) at 2 g/10 6 cells, biotin-conjugated anti-mouse Pan-NK (DX5, rat IgM; PharMingen) at 1 g/10 6 cells, and allophycocyanin-conjugated anti-mouse TER-119 (PharMingen) at 0.2 g/10 6 cells. TER-119 reacts with a molecule associated with glycophorin A and marks the late erythroblasts and mature erythrocytes (19) . To detect cells infected with F-MuLV, MAb 720 (29) reactive with F-MuLV gp70 but not with any other mouse retrovirus was purified and conjugated with biotin as described previously (12, 22, 29) . R-PE-conjugated streptavidin (PharMingen) was used for staining with the biotin-conjugated antibodies. All staining reactions were performed in the presence of 0.25 g of anti-mouse CD16/CD32 (PharMingen)/10 6 cells as described previously (12) , to prevent the binding of MAb to Fc receptor-expressing cells. Cells were also incubated with isotype-matched control antibodies purchased from the same suppliers, and staining patterns obtained with these negative control antibodies were used to draw demarcation lines that separate positively stained cells from those not stained. Multicolor flow cytometric analyses were performed with a Becton Dickinson FACScalibur and CellQuest software (Becton Dickinson Immunocytometry Systems, San Jose, Calif.). Mature erythrocytes and dead cells were excluded from the analyses by setting a polygonal gate in the dot plots showing intensities of forward scatter and the fluorescence for 7-aminoactinomycin D.
Purification of T-cell subsets and NK cells. Purification of T-cell subsets and NK cells from the spleens of FV-infected mice was performed by using Abconjugated magnetic microbeads and a magnetic cell sorter I (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). Spleen cells were first treated with Trisbuffered ammonium chloride solution to lyse erythrocytes and incubated with anti-B220 MAb-conjugated magnetic beads to remove B cells by passing them through a negatively selecting CS column. To purify CD4 ϩ T cells, B220 Ϫ cells were incubated with anti-CD8 MAb-conjugated magnetic beads, passed through a CS column to remove CD8 ϩ cells, and then incubated with anti-CD4 MAbconjugated microbeads to positively select CD4 ϩ cells by passing them through a VS column. Cells not retained in the column were collected as a CD4 Ϫ CD8 Ϫ (double-negative) population. Multicolor flow-cytometric analyses revealed that the resultant CD4 ϩ T-cell preparation was 99.2% positive for CD4. CD8 ϩ cells were similarly purified from B220 Ϫ cells by positively selecting CD8 ϩ cells. This preparation was 97 to 98% CD8 ϩ in repeated experiments. To purify cells expressing the NK marker DX5, the B220 Ϫ population of spleen cells was incubated with anti-mouse Pan-NK (DX5) MAb-conjugated microbeads, and cells expressing this marker were positively selected as a DX5 ϩ population. Depletion of NK cells in vivo. Anti-asialo-ganglio-N-tetraosylceramide (antiasialo-GM 1 ) rabbit Ab (11) and control normal rabbit serum were purchased from Wako Pure Chemicals (Osaka, Japan). CB6F 1 mice immunized once with peptide i 25 days before FV inoculation were injected intravenously with 400, 160, or 60 g of anti-asialo-GM 1 Ab/dose at 1 day prior to FV inoculation and 2, 5, 8, and 11 days after the virus infection. NK cell activity was tested on days 7, 9, and 11 postinoculation. Since administration of any of the above three amounts of anti-asialo-GM 1 Ab resulted in undetectable NK cell activity, 60 g of anti-asialo-GM 1 Ab/dose was adopted for analyzing the effect of NK cell depletion on protective immunity induced with the peptide vaccine.
Assays for proliferative responses of T cells. CD4 ϩ T cells were purified from FV-infected CB6F 1 
RESULTS

Protection of highly susceptible CB6F 1 mice against Friend retrovirus infection with a single-epitope CD4
؉ T-cell vaccine. CB6F 1 mice are highly susceptible to FV-induced leukemia, and most mice of this strain died by 60 days after inoculation of 5, 15, or 50 SFFU of FV (A. Niwa, N. Iwanami, H. Uenishi, N. Tabata, H. Yamagishi, and M. Miyazawa, submitted for publication). When control CB6F 1 mice that had been given CFA emulsion without a peptide were infected with 150 SFFU of FV, Ͼ95% of them died by postinoculation day (PID) 60 (Fig. 1a) . On the other hand, Ͼ90% of CB6F 1 mice immunized only once with 10 g (5 nmol) of peptide i survived longer than 60 days after infection with the same dose of FV. When infected mice were killed at PID 44 in a separate experiment, none of the mice immunized with peptide i showed splenomegaly, while the control mice that had died by that time or were killed at PID 44 had an enlarged spleen weighing Ͼ2.5 g (Fig. 1b) . Thus, it was clear that immunization with the singleepitope peptide i prevented the development of FV-induced leukemia and protected highly susceptible CB6F 1 mice from leukemic death.
Kinetics of the activation of immune mechanisms in FVinfected mice. CB6F 1 mice were either immunized with 10 g of peptide i/mouse or given CFA emulsion without a peptide and infected with FV 4 weeks later. Groups of mice were killed at regular intervals, and the numbers of cells expressing the late erythroid cell marker TER-119, F-MuLV gp70, CD4, CD8, and the early activation marker CD69 were measured by multicolor flow cytometry. TER-119 marks late erythroblasts and mature red blood cells but not erythroid burst-forming units (BFU-E) or erythroid CFU (CFU-E) (19) . Erythroblasts detectable with TER-119 increased slowly between 3 and 7 days after FV inoculation, and these cells showed an abrupt increase in number at PID 8 in the control mice (Fig. 2a) . A similar pattern of increase in the number of F-MuLV-infected cells was also observed in the control mice (Fig. 2b) . Dualcolor analyses revealed that Ͼ80% of TER-119 ϩ cells were F-MuLV gp70 ϩ after PID 5 in the control mice given CFA without a peptide. Since the SFFV component of FV induces proliferation and terminal differentiation of late BFU-E and CFU-E by stimulating them through erythropoietin receptor, and since mouse bone marrow BFU-E stimulated with erythropoietin usually produce erythroid cell bursts within 5 to 8 
days (16), the observed rapid expansion of TER-119
ϩ cells in the FV-infected control mice quite possibly reflects the burst formation from initially infected BFU-E. In contrast to the rapid expansion of FV-infected erythroid cells in the control mice, TER-119 ϩ cells showed only a transient increase peaking at PID 5 in mice immunized with peptide i (Fig. 2a) . The number of F-MuLV-infected cells also stayed at a low level in the immunized mice. These results, along with the previous demonstration that numbers of F-MuLV-producing cells detected as infectious centers decreased between 7 and 11 days after FV infection in (B10.A ϫ A.BY)F 1 mice immunized with peptide i (22) , suggest that some effector mechanisms were activated in the immunized mice at around 5 to 7 days after FV infection to reduce the number of FV-infected erythroid cells.
In fact, numbers of both CD4 ϩ and CD8 ϩ T cells increased between PID 5 and 9. As shown in Fig. 2c , a significant increase in the absolute number of CD4 ϩ T cells was observed at PID 7 in both immunized and control CB6F 1 mice, and the number of CD4 ϩ T cells continued to increase until PID 9 in immunized mice. A similar increase in the number of CD8 ϩ T cells that peaked at PID 7 was observed in the control mice given CFA alone (Fig. 2d ). In the immunized mice the peak of CD8 ϩ T-cell number was lower, but this population of T cells also continued to increase until PID 9. It is interesting that only in immunized mice was another phase of increase in the number of CD4 ϩ and CD8 ϩ T cells observed at PID 13 ( Fig. 2c and d ). In uninfected CB6F 1 mice only 3% of CD8 ϩ cells expressed the early activation marker CD69. The CD69 ϩ population among CD8 ϩ T cells increased transiently to 7% at PID 8 in the control mice given CFA alone but rapidly decreased to 2% at PID 11. In contrast, 13% of CD8 ϩ cells were CD69 ϩ at PID 8 in immunized mice, and the percentage of CD69 ϩ activated cells among CD8 ϩ T cells still increased to 14% at PID 11 in mice immunized with peptide i (data not shown). Thus, proliferation and activation of T cells were observed in both immunized and unimmunized control mice after FV infection, but T-cell proliferation and activation of CD8 ϩ T cells was apparently prolonged in mice immunized with peptide i.
Detection and identification of cytotoxic effector cells in FV-infected mice. Cytotoxicity assays were performed by using spleen cells from FV-infected mice as effector cells without in vitro restimulation and FV-induced leukemia cells as target cells. In repeated preliminary experiments, a peak in activities of cytotoxic effector cells capable of lysing FV-induced leukemia cells were observed at around PID 7 and 9 in mice immunized with peptide i (data not shown). This was in accordance with the reduction in the number of TER-119 ϩ erythroid cells in immunized mice observed between 5 and 7 days after FV inoculation and coincidental proliferation of CD4 ϩ and CD8 ϩ T cells in vivo (Fig. 2) . Thus, in the following experiments effector cells were prepared at PID 7 and 9 and separated into CD8 ϩ , CD4
ϩ , and double-negative populations using a magnetic cell sorter. In six repeated experiments performed at PID 7 and 9, CD8 ϩ T cells isolated from mice immunized with peptide i always showed low but consistent levels of cytotoxicity against FV-induced leukemia cell lines FBL-3 and Y57-2C (Fig. 3) . However, chemically induced T-lymphoma cells of the same H-2 genotype, EL-4, were not lysed by these effector cells. Interestingly, similar levels of cytotoxic activity of CD8 ϩ T cells were also detected after FV inoculation in the control mice given CFA alone. The same two lines of FV-induced leukemia cells were also lysed in a dose-dependent manner by CD4 ϩ effector cells isolated from peptide-immunized CB6F 1 mice in four of the six repeated experiments. Also, similar Ϫ spleen cells were separated into CD8 ϩ , CD4 ϩ , and CD4 Ϫ CD8 Ϫ populations, and their cytotoxic activities against FBL-3 (E), Y57-2C (Ⅺ), and EL-4 (F) cells were tested by incubating the effector and labeled target cells for 12 h. Representative data obtained from a set of experiments performed at PID 9 are shown here, and the results obtained from the six repeated experiments were consistent with these charts.
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on August 28, 2017 by guest http://jvi.asm.org/ killing activities of CD4 ϩ effector cells isolated from peptideimmunized, FV-infected CB6F 1 mice were detected in additional experiments (see Fig. 7 ). CD4 ϩ T cells isolated from the control mice showed no or only marginal killing activities in repeated experiments (Fig. 3) .
To confirm the observed cytotoxic effector function exerted by CD4 ϩ T cells, CD4 ϩ T-cell clones specific for F-MuLVencoded antigens were tested for their killing activities. SB14-31 cells that recognize the N-terminal epitope represented by peptide fn induced significant lysis of FBL-3 leukemia cells in vitro (Fig. 4a) . Unexpected dominance of cells expressing NK markers among cytotoxic effector cells in FV-infected mice. When CD4 Ϫ CD8 Ϫ cells from FV-infected CB6F 1 mice were tested as effectors, they showed unexpectedly high cytotoxicities against FV-induced leukemia cells at lower E:T ratios than CD8 ϩ and CD4 ϩ T cells in all six repeated experiments performed at PID 7 and 9 (Fig. 3) . However, EL-4 lymphoma cells that shared a homozygous H-2 b haplotype with the FV-induced leukemia cells were not lysed effectively by this population of spleen cells prepared from FV-infected mice. The doublenegative populations of spleen cells from both immunized and control mice showed similar levels of cytotoxicity against FVinduced leukemia cells. Fluorescence-activated cell sorting analyses of the double-negative population revealed that in both immunized and unimmunized mice, 10 to 30% of these cells were positive for the NK cell marker NK-1.1. Thus, to further identify the characteristics of effector cells in the double-negative population, NK cells were purified from B220 Ϫ cells based on their expression of another surface marker defined by MAb DX5 (Pan-NK). Positive selection of DX5-expressing cells was performed by using B220
Ϫ cells as the starting material, instead of CD4 Ϫ CD8 Ϫ cells, because the yield of B220 Ϫ CD4 Ϫ CD8 Ϫ cells was usually around 2% of the total spleen cells, and it was impractical to obtain a large enough number of DX5 ϩ effector cells from such a small starting cell number of the double-negative population. A large proportion of the cells selected for the expression of the Pan-NK marker were positive for both NK cell markers DX5 and NK-1.1 (Fig.  6b ). These cells, obtained from immunized CB6F 1 mice at both 7 ( Fig. 6c) and 9 (Fig. 6d) days after FV inoculation, showed strong killing activity against standard NK target YAC-1 cells and two lines of FV-induced leukemia cells at very low E:T ratios. However, NK-resistant EL-4 cells were not efficiently lysed by the same effector cells. A similar level of killing of YAC-1 cells and FV-induced leukemia cells was observed when the DX5 ϩ NK cell population was obtained from the control mice given CFA alone and tested for cytotoxicity at PID 7 and 9 (data not shown). On the other hand, B220
Ϫ cells depleted of the DX5 ϩ population lost most of the killing activity against YAC-1 cells and showed a low level of cytotoxicity against the FV-induced leukemia cells at higher E:T ratios, confirming that DX5 ϩ cells constitute the bulk of cytotoxic effector cells in the spleens of FV-infected mice at this early stage.
Role of cells expressing NK markers in vaccine-induced resistance against FV infection.
Since cells lacking CD4 and CD8 and expressing DX5 constituted the majority of cytotoxic effector cells at the point when numbers of FV-infected erythroid cells were being reduced in immunized mice, and since FV-induced leukemia cells were shown to be susceptible to killing by DX5 ϩ cells, the possible role of NK cells in vaccineinduced resistance against FV infection was tested by depleting NK cells from immunized mice. CB6F 1 mice were first immunized with peptide i and were injected with anti-asialo-GM 1 Ab before and after FV inoculation to deplete cells expressing this NK cell marker in vivo. Effects of the injection of various amounts of anti-asialo-GM 1 Ab were first assessed by testing YAC-1-killing activity of the spleen B220 Ϫ cells. After four repeated injections of 60 g of anti-asialo-GM 1 Ab each, NK cell activity of spleen B220 Ϫ cells at PID 9 became undetectable (Fig. 7b) , while mice injected with control rabbit serum , and CD4 Ϫ CD8 Ϫ populations were purified as described for the experiments shown in Fig. 3 from CB6F 1 mice injected with anti-asialo-GM 1 Ab (f, h, and j) or from those injected with control rabbit serum (e, g, and i). The experiments were performed twice at PID 7 and 9, and the results from the repeated experiments were consistent with the representative data shown here. Target cells used were YAC-1 (⌬), FBL-3 (E), and EL-4 (F). retained NK cell activity (Fig. 7a) . Flow cytometry analyses demonstrated that the DX5 ϩ NK-1.1 ϩ population of cells in the spleen of the mice injected with anti-asialo-GM 1 Ab was markedly reduced (Ͻ0.4% [ Fig. 7d ]) in comparison with the readily discernible cluster of DX5 ϩ NK-1.1 ϩ cells among the spleen cells of the control mice (Fig. 7c) . Cytotoxic activities of different cell populations were assayed by separating effector cells from the peptide-immunized and anti-asialo-GM 1 Abinjected mice with the magnetic cell sorting system. In two repeated experiments performed at PID 7 and 9, both CD8 ϩ and CD4
ϩ cell populations showed low cytotoxic activity against FV-induced leukemia cell line FBL-3, regardless of whether the mice were injected with anti-asialo-GM 1 Ab or normal rabbit serum (Fig. 7e to h) . These results were consistent with those shown in Fig. 3 , confirming the low but reproducible level of cytotoxic activity of CD8 ϩ and CD4 ϩ effector cells induced after FV infection in mice immunized with peptide i. In addition, the CD4 Ϫ CD8 Ϫ population of the spleen cells from the control mice injected with normal rabbit serum showed strong cytotoxic activities against both YAC-1 NK target cells and FLB-3 FV-induced leukemia cells (Fig. 7i) . EL-4 cells were not lysed by any of the above effector cells. However, the killing activities of the CD4 Ϫ CD8 Ϫ population were markedly reduced in mice injected with the anti-asialo-GM 1 Ab (Fig. 7j) , confirming that the majority of effector cells detectable as the double-negative cells were cells expressing the NK markers. Importantly, however, the injection of anti-asialo-GM 1 Ab did not affect the number or function of CD4 ϩ and CD8 ϩ populations of T cells in peptide-immunized mice. Flow-cytometric analyses revealed no significant difference in percentages of CD4 ϩ and CD8 ϩ cells in the spleen and the total nucleated-cell number between the anti-asialo-GM 1 -injected and normal rabbit serum-injected groups of peptideimmunized CB6F 1 mice at PID 7 and 9 ( Fig. 8a and b) . Furthermore, CD4
ϩ T cells purified from the anti-asialo-GM 1 -injected mice showed antigen-specific proliferative responses upon stimulation with various concentrations of peptide i that were not significantly lower than the responses exerted by the same T-cell subpopulation isolated from the control mice ( Fig.  8c and d) . Nevertheless, when the mice depleted of NK cell activity were monitored for the development of FV-induced leukemia, Ͼ95% of the immunized mice injected with the anti-asialo-GM 1 Ab died within 60 days after FV inoculation, showing a survival curve similar to that of unimmunized control mice (Fig. 8e) . On the other hand, Ͼ75% of the immunized control mice given normal rabbit serum survived past Fig. 7g and h were also tested for their proliferative activities in response to stimulation with peptide i. CD4 ϩ T cells purified from the mice injected with anti-asialo-GM 1 Ab (d) and those purified from control mice given normal rabbit serum (c) were incubated with X-irradiated syngeneic spleen cells and the indicated amount of peptide i (E). As controls, the CD4 ϩ T cells purified from the anti-asialo-GM 1 Ab-injected mice were also stimulated with an endogenous retroviral env-derived peptide i e (F) and the influenza virus nucleoprotein-derived peptide NP 366-374 (‚). Experiments were performed twice, and results obtained from the repeated experiments were consistent with the representative data shown here. (e) Development of FV-induced leukemia in CB6F 1 mice immunized with peptide i. Mice were either immunized with 10 g of peptide i each (E, ‚, Ⅺ) or given CFA alone (F). Two groups of the immunized mice were then injected with anti-asialo-GM 1 Ab (‚) or control rabbit serum (Ⅺ), while the remaining group (E) was not injected with any Ab. All mice were inoculated with 150 SFFU of FV.
PID 60. These results clearly show that NK cells are required for vaccine-induced resistance against FV infection.
DISCUSSION
FV causes fatal erythroleukemia in immunocompetent adult mice through a multistep process. In the first step, SFFV gp55 expressed on cell surfaces interacts with the erythropoietin receptor and induces mitogenic activation and differentiation of infected erythroid progenitor cells in a polyclonal fashion (16, 21) . This is followed by repeated integration of proviral DNA into the chromosomes of expanded erythroid cells and the consequent emergence of an immortalized leukemia cell clone (16) . The primary targets for SFFV-induced polyclonal proliferation are late BFU-E and CFU-E, which are responsive to erythropoietin.
Several host genes affect the development and progression of FV-induced disease. These include the genes affecting the entry and replication of F-MuLV in target cells, those regulating and interfering with erythropoietin receptor-induced growth potentiation of erythroid progenitor cells, and those regulating immune responses against the viral antigens (2, 16). Immune mechanisms affecting FV infection and their genetic regulation have been studied mainly in mice with a (C57BL ϫ A)F 1 background, because these mice show spontaneous resistance against FV infection depending on their composition of alleles at MHC loci (2, 24, 25) . On the other hand, mice possessing a BALB/c background are extremely susceptible to FV-induced disease. In fact, when CB6F 1 mice used in the present study are inoculated with a low dose of FV, 95 to 100% die within 60 days postinoculation. This is striking because (B10.A ϫ A/WySn)F 1 mice, which have typically been used as a strain susceptible to FV, show mortality rates of 70 to 80% at 90 to 100 days after FV inoculation (24) . It should be emphasized, therefore, that a single immunization with the CD4 ϩ T-cell epitope vaccine, peptide i, induced almost complete protection against FV infection even in this highly susceptible strain of mice.
Actual effector mechanisms activated after FV inoculation in mice immunized with the single-epitope peptide i seem complex. A transient increase in the number of CD4 ϩ and CD8 ϩ T cells in the spleen and the expression of early activation marker CD69 on CD8 ϩ T cells coincided with the suppression of the growth of TER-119 ϩ erythroid cells and FMuLV-infected cells in immunized mice (Fig. 2) . However, this transient increase in the number of CD4 ϩ and CD8 ϩ T cells was also observed in unimmunized control mice after FV infection, although the increase in number and activation of T cells in vivo was prolonged in mice immunized with peptide i. Despite the apparent proliferation and the expression of the early activation marker, cytotoxic activity of CD8 ϩ T cells at the time of the reduction of erythroid cell number in immunized mice was not high (Fig. 3) . Moreover, similar levels of cytotoxic activities were observed when CD8 ϩ T cells were separated after FV infection from the control mice given CFA alone. The observation that CD8 ϩ CTL were activated in the control mice after FV infection is not surprising, because FVspecific CD8
ϩ CTL have been detected in unimmunized (B10 ϫ A.BY)F 1 mice during their spontaneous recovery from FV-induced splenomegaly (3, 30) . Furthermore, CTL activities were also detected in H-2 a/b (B10.A ϫ A.BY)F 1 mice after inoculation with a low dose of FV (2) . Thus, induction of CD8 ϩ CTL is commonly observed in FV-infected mice irrespective of whether they have been immunized with an anti-FV vaccine prior to the virus inoculation. For this reason, it is unlikely that the effect of peptide immunization, especially the suppression of the growth of FV-infected erythroid cells observed as early as 5 to 7 days after virus inoculation, can be explained by the activation of CD8 ϩ CTL alone. In this regard, a peak in CTL activities was observed at around 2 weeks after FV inoculation both in mice showing spontaneous recovery from FV infection and in those immunized with the recombinant vaccinia virus expressing the F-MuLV env gene (3, 9, 30) . This is 1 week later than the point at which the absolute number of CD4 ϩ and CD8 ϩ T cells increased and numbers of FV-infected erythroid cells were reduced in mice immunized with peptide i (Fig. 2) (22) . Thus, previously documented CTL activities peaking at PID 14 or later may not be the cause of the control of FV infection but might reflect the cytokine-induced expansion of CD8 ϩ effector cells resulting from earlier immune responses that are actually related to the containment of virus infection. Given this, CD8
ϩ CTL may also be involved in the control of leukemia development at a later stage, perhaps by suppressing the emergence or growth of monoclonal erythroleukemia cells.
In addition to CD8 ϩ T cells, CD4 ϩ T cells were also shown to exert killing activities against FV-induced leukemia cells (Fig. 3 to 5 and 7) . This killing by CD4 Ϫ CD8 Ϫ cells showed higher cytotoxic activities at E:T ratios lower than those required for the killing of the same target cells by CD4 ϩ or CD8 ϩ effector cells (Fig. 3) . The double-negative population contained 10 to 30% DX5 ϩ cells. DX5 ϩ cells separately isolated from the B220
Ϫ spleen cell population of the peptide-immunized and FV-infected mice showed effective killing of the FV-infected leukemia cells at E:T ratios three-to sixfold lower than those required for the double-negative population (Fig. 6) . These results suggest that the majority of the effector cells contained in the double-negative population are probably DX5 ϩ cells. Furthermore, these DX5 ϩ cells also killed the standard NK target YAC-1 cells very efficiently. Expression of both NK-1.1 and DX5 and efficient killing of YAC-1 target cells are phenotypic and functional markers of mouse NK cells. The NK cell nature of the CD4 Ϫ CD8 Ϫ effector cells was further confirmed by depleting asialo-GM 1 ϩ cells by injecting the relevant Ab into peptide-immunized and FV-infected mice. When antiasialo-GM 1 Ab was repeatedly injected into CB6F 1 mice that had been immunized with peptide i and infected with FV, the CD4 Ϫ CD8 Ϫ population showed markedly reduced killing activity for both YAC-1 and FBL-3 target cells (Fig. 7) . Thus, it is reasonable to conclude that the majority of effector cells contained in the B220 Ϫ CD4 Ϫ CD8 Ϫ population of the spleen cells were positive for multiple NK cell markers, and these NK cells effectively kill both YAC-1 target cells and two independent lines of FV-induced leukemia cells, FBL-3 and Y57-2C.
Similarly high NK cell activities were detected in macaques at 1 to 2 weeks after infection with a pathogenic strain of simian immunodeficiency virus (10) . Interestingly, the transient increase in NK cell activity was found to be inversely correlated with plasma antigenemia levels when cytotoxic activity against NK target K562 cells and levels of viral p27 in plasma in individual macaques were compared (10) . That report suggested that NK cell killing of virus-infected cells might be involved in the containment of retroviral infection in its earlier stage. This hypothesis has been directly examined in the present study by depleting NK cells in FV-infected mice. In fact, vaccine-induced resistance against FV infection was totally abrogated when YAC-1-killing NK cell activity was eliminated by treating immunized mice with anti-asialo-GM 1 Ab. Slifka et al. (37) recently showed that in a model of lymphocytic choriomeningitis virus infection in C57BL/6 mice, Ն90% of virus antigen-specific CD8 ϩ T cells and nearly 90% of CD4 ϩ T cells responding to the viral antigen express asialo-GM 1 , and 30 to 40% of virus-specific CD8 ϩ cells express DX5 at 8 days after lymphocytic choriomeningitis virus infection. If this observation can be generalized to any virus infection, one can argue that in our experiments whose results are shown in Fig.  7 and 8, we might have depleted asialo-GM 1 -expressing CD8 ϩ and/or CD4 ϩ T cells by injecting anti-asialo-GM 1 Ab into peptide-immunized mice. In addition, the DX5 ϩ population of effector cells which we used in the experiment whose results are shown in Fig. 6 might have included DX5 ϩ , CD8 ϩ , and/or DX5 ϩ CD4 ϩ effector cells, and thus, we might have detected killing activities of such virus-specific effector T cells in addition to NK cell activities. However, these possibilities are unlikely for several reasons. First, if viral-antigen-specific T cells expressed NK cell markers in FV-infected mice, they must have been coseparated into the CD8 ϩ and CD4 ϩ populations of the effector cells in the experiments whose results are shown in Fig. 3 and 7 . Thus, the double-negative population, which was actually Ն92% negative for CD4 and CD8 expression as confirmed by flow-cytometric analyses, contained very few, if any, T cells expressing the NK cell markers. Nevertheless, the majority of the cytotoxic activity was detected in the doublenegative population, indicating that in the early stage of FV infection non-T NK cells, rather than CD8 ϩ or CD4 ϩ effector T cells expressing NK cell markers, exert the most efficient killing activities against the virus-infected cells. Second, in a few preliminary experiments (results not shown), we purified DX5 ϩ cells from the B220 Ϫ CD4 Ϫ CD8 Ϫ population of spleen cells. Because of the very small number of the effector cells finally obtained, cytotoxicity assays were performed with limited E:T ratios. However, these B220 Ϫ CD4 Ϫ CD8 Ϫ DX5 ϩ cells showed a high efficiency of killing of both YAC-1 and FBL-3 target cells. Third, when the minimal required amount of anti-asialo-GM 1 Ab was used for the depletion of NK cell activity, the total nucleated-cell number and percentages of both CD4 ϩ and CD8 ϩ T cells in the spleen did not change significantly in comparison with those in the control mice given normal rabbit serum (Fig. 8) . Furthermore, the viral epitopespecific proliferative responses of CD4 ϩ T cells were not significantly affected in the mice depleted of asialo-GM 1 -expressing cells. Thus, at least the number and the above viral antigenspecific function of T cells were not affected by injection of anti-asialo-GM 1 Ab. In addition, the low but reproducible killing activity of CD8 ϩ T cells against FV-induced leukemia cells was still detectable in the mice depleted of asialo-GM 1 ϩ NK cells. Thus, it is appropriate to conclude that the complete abrogation of the peptide-induced protection against FV infection observed in mice injected with anti-asialo-GM 1 Ab (Fig. 8) is mainly attributable to the elimination of NK cell functions exerted by the CD4 Ϫ CD8 Ϫ cells. Since NK cell activity against FV-infected leukemia cells was detectable in both immunized and control mice after FV infection, detected NK cell function alone cannot explain the effectiveness of peptide immunization. Rather, it is possible that some other effector mechanisms activated only in immunized mice cooperate with NK cells to effectively eliminate FV-infected cells. These may include accelerated production and class switching of virus-neutralizing antibodies detectable at as early as 7 days after FV inoculation in vaccinated mice (22) , and CD4 ϩ cytotoxic cells detected in the present study (Fig. 3 to 5 and 7) . NK cells might also be required as a source of cytokines necessary for the activation of other effector mechanisms. Enhanced NK cell activity in the early stage of FV infection detected in the present study may be due to the administration of CFA before FV inoculation, since the control mice were given CFA emulsion without a peptide. However, in our preliminary experiments, B220 Ϫ CD4 Ϫ CD8 Ϫ cells purified from unmanipulated CB6F 1 mice at 7 and 9 days after FV infection showed very efficient killing of YAC-1 and FVinduced leukemia cells at low E:T ratios. In fact, the doublenegative cells prepared at PID 9 from the mice that had received no adjuvant showed 50 and 35% killing of YAC-1 cells at E:T ratios of 150:1 and 75:1, respectively, and 32 and 28% killing of FBL-3 cells at the same respective E:T ratios. These killing activities were comparable to those shown in Fig. 3 and 7. Thus, it is possible that infection with FV itself, without stimulation of the immune system with CFA, induces enhanced NK cell activity.
Detection of cytotoxic effector cells from FV-infected mice has been performed without in vitro restimulation of the effector cell population (2, 3, 7, 30) . Because of this, an incubation of effector cells with labeled target cells for a longer period than in other systems was required to detect significant killing activities. Although it has not been formally documented, many researchers, including us, have attempted to restimulate spleen cells from FV-infected mice with irradiated FV-induced leukemia cells in vitro, without getting selective augmentation of antigen-specific killing activity. In our experience, restimulation of spleen cells from FV-infected mice always results in a nonspecific killing activity against uninfected target cells like P815 mastocytoma cells, causing difficulties in detecting MHCrestricted, antigen-specific cytotoxicity. It is clear now that FVinduced leukemia cells are recognized effectively by NK cells, and NK cells are activated in FV-infected mice. It is, therefore, possible that in attempts to restimulate cytotoxic effector cells in vitro by coculturing spleen cells with FV-induced leukemia cells, NK cells are expanded and stimulated to exert a high killing activity.
In conclusion, FV-induced leukemia cells are recognized and killed by NK cells, and NK cells are activated in the early stage of FV infection. NK cells are necessary for vaccineinduced resistance against FV infection, but NK activity alone cannot explain the rapid elimination of FV-infected erythroid cells that takes place in mice immunized with the CD4 ϩ T-cell vaccine. Thus, antiretroviral vaccine strategies may require not only direct priming of CD8 ϩ effector cells and induction of virus-neutralizing antibodies but also proper stimulation of NK cell activities, which may also lead to the induction of T-helper type 1 responses advantageous for the control of retroviral infections.
